Each tablet contains: Lacidipine 4 mg.
Initially 2 mg as a single daily dose, preferably in the morning; increased after 3-4 weeks to 4 mg daily, then if necessary to 6 mg daily.
Cardiogenic shock, unstable angina, aortic stenosis; avoid within 1 month of myocardial infarction; acute porphyria.
Cardiac conduction abnormalities; poor cardiac reserve.
Pregnancy: Manufacturer advises to avoid; may inhibit labour.
Breast-feeding: Manufacturer advises to avoid; no information available.
Flushing, palpitation, oedema; headache, dizziness; rarely gastro-intestinal disturbances, gum hyperplasia, aggravation of angina, mood disturbances, asthenia, polyuria, muscle cramps, skin rash (including pruritus and erythema).
C08CA09 - lacidipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.